Patel Chem Specialities Completes INR 16.69 Cr Anchor Round With Participation From Bengal Finance & Investment Private Limited And Others

Mumbai (Maharashtra) [India], July 25: Patel Chem Specialities Limited, a prominent manufacturer of cellulose- and starch-based pharmaceutical excipients, has successfully concluded its Anchor Book allocation ahead of the Initial Public Offering (IPO) scheduled to open on Friday, July 25, 2025.

Among the anchor investors, Bengal Finance & Investment Private Limited emerged as the lead participant, being allotted 5,96,800 equity shares amounting to ₹5.01 crore, representing 30.03% of the total anchor portion.

Other anchor participants include Meru Investment Fund PCC, Arnesta Global Opportunities Fund, Zeal Global Opportunities Fund, Necta Bloom VCC – Regal Fund, Venturex Fund I, Vikasa India EIF I Fund, and Belgrave Investment Fund.

The company has allocated 19,87,200 equity shares to eight marquee anchor investors at ₹84 per share (including a premium of ₹74).

Sr. No. Name of the Anchor Investor No. of Equity Shares allocated Total Amount (In ₹ Cr) % of Anchor Investor Portion
1 Bengal Finance & Investment Private Limited 5,96,800 5.01 30.03%
2 Meru Investment Fund PCC- Cell 1 3,60,000 3.02 18.12%
3 Arnesta Global Opportunities Fund PCC – Arnesta Global Fund 1 2,38,400 2.00 12.00%
4 Zeal Global Opportunities Fund 2,38,400 2.00 12.00%
5 Necta Bloom VCC-Regal Fund 1,93,600 1.63 9.74%
6 Venturex Fund I 1,20,000 1.01 6.04%
7 Vikasa India EIF I Fund – Share Class P 1,20,000 1.01 6.04%
8 Belgrave Investment Fund 1,20,000 1.01 6.04%
# Total 19,87,200 16.69 100.00%

Mr. Swapnilsagar Vithalani, Co-founder & Director, Cumulative Capital Private Limited:

“At Cumulative Capital, we are proud to have played a central role in shaping and executing Patel Chem Specialities’ IPO journey—from strategic planning and valuation to investor outreach and structuring. This successful anchor allocation reflects our ability to align credible, long-term capital with high-potential companies in niche, export-driven sectors. Patel Chem is a classic example of a fundamentally strong business with a differentiated product portfolio, global certifications, and a clear path for expansion. As merchant bankers, we remain committed to supporting the company’s next phase of growth—unlocking value, enhancing governance, and building sustained institutional interest beyond the IPO.”

If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.

Business

Fischer Medical Subsidiary, Time Medical India, Collaborates with Dr. Cherian to Pioneer Next-Generation AI-Enabled MRI System

Mumbai (Maharashtra) [India], November 4: Fischer Medical Ventures Limited (FISCHER | 524743 | INE771F01041), Time Medical International Ventures (I) P LTD, the wholly owned subsidiary of Fischer Medical Ventures Limited, today announced a strategic collaboration with globally acclaimed neurosurgeon, educator, and innovator Dr Iype Cherian. The collaboration’s sole purpose is the development of DRIS–iMRI Medharanya, a […]

Read More
Agartala Business Dr. Saikat Kar innovation Neurotech Startup Science

From Agartala to Global Innovation: How Tripura’s First Neurotech Startup is Bridging Brain Science with Grassroots Impact

Agartala (Tripura) [India], November 4: In a region celebrated for tea gardens and handicrafts rather than technological ambition, a quiet revolution is unfolding. Codonmind Nexus Private Limited, the Northeast’s pioneering neurotechnology startup, is developing brain-computer interface devices and advanced neurological research tools positioned to compete with national players in a market projected to reach USD […]

Read More
Business Harsheep Hortico Limited

Harshdeep Hortico Reports Strong H1 FY26 with Net Profit of INR 5.7 crore

Mumbai (Maharashtra) [India], November 4: Harsheep Hortico Limited (BSE: HARSHDEEP), specializing in the manufacture and export of pots, planters, garden accessories, and outdoor furniture; announced its Unaudited financials for H1 FY26. Key H1 FY25 Financial Highlights Key Financial Highlights (Consolidated) – H1 FY2025-26 Revenue for H1 FY2025–26 was ₹37.84 crore, compared to ₹24.09 crore in […]

Read More